We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Close to 90 Percent of CML Patients On Gleevec Alive After Five Years
Close to 90 Percent of CML Patients On Gleevec Alive After Five Years
June 14, 2006
Close to 90 percent of patients suffering from Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) survived five years after they started taking Gleevec (imatinib), Novartis announced.